These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34025731)

  • 1. Salvage brachytherapy for locally recurrent prostate cancer after single-fraction 19 Gy high-dose-rate brachytherapy: toxicity, prostate-specific antigen kinetics, and cancer control.
    Mayrata E; Espinosa JM; Büchser D; Casquero F; Suárez F; González A; Minguez P; Pérez JF; Miguel IS; Cacicedo J; Gómez-Iturriaga A
    J Contemp Brachytherapy; 2021 Feb; 13(1):12-17. PubMed ID: 34025731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage brachytherapy in prostate local recurrence after radiation therapy: predicting factors for control and toxicity.
    Henríquez I; Sancho G; Hervás A; Guix B; Pera J; Gutierrez C; Abuchaibe O; Martínez-Monge R; Tormo A; Polo A
    Radiat Oncol; 2014 Apr; 9():102. PubMed ID: 24885287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer.
    Ecke TH; Huang-Tiel HJ; Golka K; Selinski S; Geis BC; Koswig S; Bathe K; Hallmann S; Gerullis H
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
    Henríquez López I; González-San Segundo C; Vegas JO; Gutierrez C; Hervas A; Cabeza Rodriguez MÁ; Valero Albarrán J; Rodríguez Villalba S; Álvarez Gonzalez A; Sancho Pardo G; Zapatero A; Álvaro PC
    Radiother Oncol; 2019 Dec; 141():156-163. PubMed ID: 31570236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage high-dose-rate brachytherapy for histologically confirmed macroscopic local relapsed prostate cancer after radical prostatectomy.
    Buchser D; Gomez-Iturriaga A; Melcon JI; Casquero F; Llarena R; Cacicedo J; Bilbao P
    J Contemp Brachytherapy; 2016 Dec; 8(6):477-483. PubMed ID: 28115952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage high-dose-rate brachytherapy for prostate cancer persistence after brachytherapy: repeated use of a polyethylene glycol hydrogel spacer.
    Hepp R; Eggert T; Schabl G; Herberholz L; Petry T; Galalae R
    J Contemp Brachytherapy; 2018 Apr; 10(2):169-173. PubMed ID: 29789766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
    Tsang YM; Tharmalingam H; Belessiotis-Richards K; Armstrong S; Ostler P; Hughes R; Alonzi R; Hoskin PJ
    Radiother Oncol; 2021 May; 158():184-190. PubMed ID: 33639192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
    Makino T; Mizokami A; Namiki M
    Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-gland salvage treatment for recurrent prostate cancer after initial definitive radiotherapy: A case series of
    Sutani S; Yorozu A; Toya K; Nishiyama T; Ozu C; Yagi Y; Nakamura K; Saito S
    J Contemp Brachytherapy; 2019 Jun; 11(3):201-206. PubMed ID: 31435426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
    Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
    Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure.
    Wojcieszek P; Szlag M; Głowacki G; Cholewka A; Gawkowska-Suwińska M; Kellas-Ślęczka S; Białas B; Fijałkowski M
    Radiother Oncol; 2016 Jun; 119(3):405-10. PubMed ID: 27165612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage prostate HDR brachytherapy combined with interstitial hyperthermia for local recurrence after radiation therapy failure.
    Kukiełka AM; Hetnał M; Dąbrowski T; Walasek T; Brandys P; Nahajowski D; Kudzia R; Dybek D; Reinfuss M
    Strahlenther Onkol; 2014 Feb; 190(2):165-70. PubMed ID: 24317192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial high-dose-rate brachytherapy as salvage treatment for locally recurrent prostate cancer after definitive radiation therapy: Toxicity and 5-year outcome.
    Jiang P; van der Horst C; Kimmig B; Zinsser F; Poppe B; Luetzen U; Juenemann KP; Dunst J; Siebert FA
    Brachytherapy; 2017; 16(1):186-192. PubMed ID: 28341011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review.
    Zhong J; Slevin F; Scarsbrook AF; Serra M; Choudhury A; Hoskin PJ; Brown S; Henry AM
    Front Oncol; 2021; 11():681448. PubMed ID: 34568012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses - 14 years of single-centre experience.
    Soatti CP; Delishaj D; D'Amico R; Frigerio C; Fumagalli IC; Bonsignore F; Sangalli G; Declich F; Arcangeli S; Ardizzoia A; Colombo A
    J Contemp Brachytherapy; 2020 Dec; 12(6):533-539. PubMed ID: 33437300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer.
    Armstrong S; Tsang Y; Lowe G; Tharmalingam H; Alonzi R; Ostler P; Hughes R; Hoskin P
    Radiother Oncol; 2021 Apr; 157():93-98. PubMed ID: 33493500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer.
    Chitmanee P; Tsang Y; Tharmalingam H; Hamada M; Alonzi R; Ostler P; Hughes R; Lowe G; Hoskin P
    Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):259-265. PubMed ID: 31708350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.